Use of sodium‐glucose cotransporter‐2 inhibitors in France: Analysis of French nationwide health insurance database
Authors' conclusion
The expansion of indications for SGLT-2i and the broadening of the target population make it essential to assess the reasons for discontinuation and review their safety profile.
Study context
- Population
- French nationwide health insurance database; incident SGLT2i users (mean age 65.0 years; 60.1% men)SGLT2i new users
- Participants
- 125,387 participants
- Outcome
- Trends in incidence and prevalence of glucose-lowering drug use; characteristics of SGLT2i new users
- Follow-up
- 2019 and 2021
Methodological detailsrepeated cross-sectional study and cohort study, French health insurance database, repeated cross-sectional 2019 and 2021, cohort of incident SGLT2i users
- Repeated cross-sectional study and cohort study
- French health insurance database
- Repeated cross-sectional 2019 and 2021
- Cohort of incident SGLT2i users
Main finding
As reported in the abstract
- Prevalence of SGLT2i use, third quarter of 2021
- 0.1%
- Prevalence of SGLT2i use thereafter
- 0.2%
- SGLT2i second most prescribed glucose-lowering drug class after metformin at end of 2021
- 0.1%
- New users with a diabetic comorbidity
- 87.6%
- Cardiovascular comorbidity at initiation, 2020 vs 2021
- 28.7% vs 40.2%
- Renal comorbidity at initiation, 2020 vs 2021
- 7.7% vs 11.8%
- Combination at initiation: metformin
- 12.5%
- Combination at initiation: metformin plus DPP-4i
- 8.1%
- One-year probability of SGLT2i persistence
- 55%
Observational data: associations, not effects.
Original publication
Use of sodium‐glucose cotransporter‐2 inhibitors in France: Analysis of French nationwide health insurance database. Diabetes Obes Metab. Published 30 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →